Yu Qian
Head Director, Analytical Project Leads, Cell Therapies Novartis AG
Seminars
Thursday 17th September 2026
Defining Potency in CAR-T & Cell Therapies to Align with FDA Expectations
2:10 pm
- Exploring FDA draft guidance on potency assurance to clarify approaches for demonstrating product functionality and consistency data
- Evaluating matrix and orthogonal potency strategies to ensure robust measurement across diverse patient groups and clinical contexts
